West Pharma (WST) Misses Q2 EPS by 22c; cuts guidance

West Pharma (NYSE: WST) reported Q2 EPS of $1.52, $0.22 worse than the analyst estimate of $1.74. Revenue for the quarter came in at $702.1 million versus the consensus estimate of $729.36 million.

GUIDANCE:

West Pharma sees FY2024 EPS of $6.35-$6.65, versus the consensus of $7.74. West Pharma sees FY2024 revenue of $2.87-2.9 million, versus the consensus of $3.01 million.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• SEGG Media sues short seller for $20M over stock report
• AES stockholders approve $10.7 billion takeover by GIP and EQT